BRAF and anaplastic ganglioglioma: In the open-label, nonrandomized, multicohort VE-BASKET study, three anaplastic gangliogliomas and two pilocytic astrocytomas with BRAF V600E mutations were treated with vemurafenib twice daily and a partial response was observed in one patient with a pilocytic astrocytoma and one with an anaplastic ganglioglioma [40].